Talaris Therapeutics Inc. (TALS)
NASDAQ: TALS
· Real-Time Price · USD
2.72
-0.02 (-0.73%)
At close: Oct 19, 2023, 10:00 PM
Talaris Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -116.86M | -112.86M | -95.56M | -71.84M | -71.48M | -69.34M | -80.23M | -82.14M | -76.48M | -71.04M | -64.27M | -56.92M | -47.51M | -39.95M | -33.03M | -26.71M |
Interest Income | -1.76M | -1.76M | -1.76M | 1.76M | 1.76M | 1.76M | 1.76M | 500.00 | 500.00 | 200.00 | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -95.2M | -89.59M | -73.64M | -59.42M | -61.74M | -62.78M | -74.77M | -78.13M | -73.89M | -69.61M | -63.54M | -56.79M | -47.83M | -40.37M | -33.85M | -27.16M |
Net Income | -95.2M | -89.59M | -73.64M | -59.42M | -60.16M | -57.66M | -68.84M | -72.2M | -69.54M | -68.8M | -63.54M | -56.79M | -47.83M | -40.37M | -33.85M | -27.16M |
Selling & General & Admin | 18.85M | 18.74M | 21.88M | 26.48M | 27.56M | 26.51M | 22.23M | 21.44M | 19.47M | 18.09M | 17.12M | 15.38M | 13.7M | 12.35M | 10.66M | 8.51M |
Research & Development | 108.44M | 104.54M | 84.55M | 39.42M | 33.5M | 32.41M | 47.13M | 56.22M | 57.01M | 52.95M | 47.16M | 41.54M | 33.81M | 27.6M | 22.38M | 18.21M |
Other Expenses | n/a | n/a | 89K | 89K | 89K | 89K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 127.28M | 123.28M | 106.52M | 65.99M | 61.15M | 59.01M | 69.36M | 77.66M | 76.48M | 71.04M | 64.27M | 56.92M | 47.51M | 39.95M | 33.03M | 26.71M |
Interest Expense | -3.68M | -3.68M | -1.76M | 3.68M | 3.68M | 5.45M | 4.35M | 2.58M | 2.58M | 812K | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 50.64M | 50.64M | 60.11M | 19.58M | 39.18M | 59.01M | 69.36M | 77.66M | 76.48M | 71.04M | 64.27M | 56.92M | 47.51M | 39.95M | 33.03M | 26.71M |
Income Tax Expense | -3.04M | -3.04M | -3.04M | n/a | -1.58M | -5.12M | -5.93M | -5.93M | -4.35M | -812K | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 25.75M | 25.69M | 25.35M | 25.77M | 25.72M | 4.27M | 4.22M | 4.18M | 4.15M | 4.14M | 41.09M | 40.98M | 40.93M | 40.67M | 27.37M | 41.24M |
Shares Outstanding (Diluted) | 25.75M | 25.69M | 25.35M | 25.77M | 25.72M | 4.27M | 4.22M | 4.18M | 4.15M | 4.14M | 41.09M | 40.98M | 40.93M | 40.67M | 27.37M | 41.24M |
EPS (Basic) | 4.67 | 4.89 | 4.14 | -6.59 | -10.81 | -13.74 | -16.5 | -13.45 | -8.9 | -5.64 | -1.56 | -1.53 | -1.31 | -1.28 | -1.26 | -1.07 |
EPS (Diluted) | 4.67 | 4.89 | 4.14 | -6.59 | -10.81 | -13.74 | -16.5 | -13.45 | -8.9 | -5.64 | -1.56 | -1.53 | -1.31 | -1.28 | -1.26 | -1.07 |
EBITDA | -123.73M | -119.73M | -102.43M | -71.84M | -61.88M | -38.17M | -48.49M | -49.85M | -53.3M | -69.24M | -62.88M | -55.94M | -46.88M | -39.39M | -32.51M | -26.23M |
EBIT | 18.07M | 18.07M | 12.97M | -18.07M | -42.15M | -58.91M | -72.01M | -77.45M | -71.78M | -69.42M | -64.27M | -56.92M | -47.51M | -39.95M | -33.03M | -26.71M |
Depreciation & Amortization | -9.82M | -9.82M | -9.86M | 221.41K | 9.82M | 10.38M | 10.98M | 11.28M | 2.16M | 1.8M | 1.39M | 976K | 623K | 560K | 522K | 490K |